Research programme: therapeutic antibodies - Dyax/Merck Serono
Latest Information Update: 30 Aug 2011
At a glance
- Originator Dyax
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 30 Aug 2011 No development reported - Preclinical for Undefined indication in Belgium (unspecified route)
- 30 Aug 2011 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 13 Mar 2008 Preclinical development is ongoing